Trends and health burden of hospitalized acute respiratory infections and impact of Haemophilus influenza immunization in a Tunisian university hospital: a twelve-year study.
Academic Medical Centers
Acute Disease
Adolescent
Adult
Child
Child, Preschool
Community-Acquired Infections
/ epidemiology
Female
Global Burden of Disease
/ trends
Haemophilus Vaccines
/ therapeutic use
Hospitalization
/ trends
Humans
Infant
Infant, Newborn
Influenza, Human
/ epidemiology
Male
Middle Aged
Respiratory Tract Infections
/ epidemiology
Retrospective Studies
Tunisia
/ epidemiology
Vaccination Coverage
/ trends
Young Adult
Hib vaccine
Respiratory Infection
Tunisia
burden
inpatients
pneumonia
trends
Journal
The Libyan journal of medicine
ISSN: 1819-6357
Titre abrégé: Libyan J Med
Pays: United States
ID NLM: 101299403
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
13
7
2021
Statut:
ppublish
Résumé
We aimed to describe the episodes and trends of admissions for community-acquired Respiratory Infections (RI) over a 12-year period and to assess the impact of Haemophilus influenza type b (Hib) vaccine on RI admissions in children aged up to 3 years. We conducted a twelve-year retrospective observational study on all community-acquired RI admitted to Fattouma Bourguiba Hospital in Monastir Governorate (Tunisia) from 1 January 2002 to 31 December 2013. RI cases were selected from the Regional Registry of Hospital Morbidity. Data were coded according to ICD-10. To assess the impact of the Hib vaccine, three cohorts were defined based on vaccine status (unvaccinated cohort, first vaccinated cohort (VC) by monovalent form and second VC by pentavalent combination). Admissions for RI represented 17.6% (CI95%: 17.3-18.1) of all communicable diseases hospitalizations (n = 6 061/34 289). The crude incidence rates (CIR) per 100,000 inh were 24.2 for upper RI (URI) and 77.5 and for Lower RI (LRI) (p < 0.0001). Pneumonias represented 53.9% of LRI. Sex-ratio (male/female) was 1.12 for URI and 1.64 for LRI (p < 0.0001). At admission, the median age was 22 years (IQR: 3-52). Admission for Pneumonia increased significantly during study period (slope 'b' = 5.16; p < 0.0001) especially in children up to 5 years old (slope 'b' = 5.53) and in elderly (slope 'b' = 2.13). Among children up to 3 years old, the CIRs per 100,000 for Hib pneumonia admission were 11.6 in Non-Vaccinated Cohort (NVC), 10.6 in Vaccinated Cohort (VC) by protocol 1 (Hib Vaccine monovalent) and 0.80 in VC by protocol 2 (pentavalent vaccine combination).The relative risk reduction was 99% for protocol 2 (p < 0.001). Admissions for RI in a tertiary level hospital were common with an increasing trend. The Hib immunization program, in particular the pentavalent combination, has had a positive impact on the reduction of related acute diseases.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to describe the episodes and trends of admissions for community-acquired Respiratory Infections (RI) over a 12-year period and to assess the impact of Haemophilus influenza type b (Hib) vaccine on RI admissions in children aged up to 3 years.
METHODS
METHODS
We conducted a twelve-year retrospective observational study on all community-acquired RI admitted to Fattouma Bourguiba Hospital in Monastir Governorate (Tunisia) from 1 January 2002 to 31 December 2013. RI cases were selected from the Regional Registry of Hospital Morbidity. Data were coded according to ICD-10. To assess the impact of the Hib vaccine, three cohorts were defined based on vaccine status (unvaccinated cohort, first vaccinated cohort (VC) by monovalent form and second VC by pentavalent combination).
RESULTS
RESULTS
Admissions for RI represented 17.6% (CI95%: 17.3-18.1) of all communicable diseases hospitalizations (n = 6 061/34 289). The crude incidence rates (CIR) per 100,000 inh were 24.2 for upper RI (URI) and 77.5 and for Lower RI (LRI) (p < 0.0001). Pneumonias represented 53.9% of LRI. Sex-ratio (male/female) was 1.12 for URI and 1.64 for LRI (p < 0.0001). At admission, the median age was 22 years (IQR: 3-52). Admission for Pneumonia increased significantly during study period (slope 'b' = 5.16; p < 0.0001) especially in children up to 5 years old (slope 'b' = 5.53) and in elderly (slope 'b' = 2.13). Among children up to 3 years old, the CIRs per 100,000 for Hib pneumonia admission were 11.6 in Non-Vaccinated Cohort (NVC), 10.6 in Vaccinated Cohort (VC) by protocol 1 (Hib Vaccine monovalent) and 0.80 in VC by protocol 2 (pentavalent vaccine combination).The relative risk reduction was 99% for protocol 2 (p < 0.001).
CONCLUSION
CONCLUSIONS
Admissions for RI in a tertiary level hospital were common with an increasing trend. The Hib immunization program, in particular the pentavalent combination, has had a positive impact on the reduction of related acute diseases.
Identifiants
pubmed: 32552441
doi: 10.1080/19932820.2020.1783048
pmc: PMC7482779
doi:
Substances chimiques
Haemophilus Vaccines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1783048Références
Cochrane Database Syst Rev. 2017 Oct 17;10:CD010089
pubmed: 29039160
Int J Environ Res Public Health. 2013 Dec 17;10(12):7257-71
pubmed: 24351745
Vaccine. 2018 Jan 8;36(3):400-407
pubmed: 29223483
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):62-9
pubmed: 25573110
J Diabetes Complications. 2015 Mar;29(2):192-5
pubmed: 25488325
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
Thorax. 2009 Oct;64 Suppl 3:iii1-55
pubmed: 19783532
Int J Chron Obstruct Pulmon Dis. 2017 Jan 17;12:313-322
pubmed: 28176888
Tunis Med. 2018 Oct-Nov;96(10-11):696-705
pubmed: 30746663
Am J Respir Crit Care Med. 2002 Apr 15;165(8):1084-92
pubmed: 11956049
Pediatrics. 2008 Feb;121(2):253-60
pubmed: 18245415
Lancet. 2012 Jun 9;379(9832):2151-61
pubmed: 22579125
Int J Cardiol. 2017 Feb 1;228:628-632
pubmed: 27883972
Rev Med Brux. 2015 Sep-Oct;36(5):410-4
pubmed: 26749630
Br J Nurs. 2012 Jan 26-Feb 8;21(2):103-6
pubmed: 22306639
Lancet. 2009 Sep 12;374(9693):903-11
pubmed: 19748399
Expert Rev Anti Infect Ther. 2003 Oct;1(3):505-16
pubmed: 15482146
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
Int J Infect Dis. 2010 Jan;14(1):e68-72
pubmed: 19497772
Epidemiol Infect. 2014 Aug;142(8):1778-88
pubmed: 24330917
Scand J Infect Dis. 2009;41(2):95-8
pubmed: 19065449
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Pediatr Infect Dis J. 2013 Sep;32(9):946-9
pubmed: 23609040
Vaccine. 2020 Jan 10;38(2):194-201
pubmed: 31653527
Lancet. 2013 Apr 20;381(9875):1341-1342
pubmed: 23369798
Int J Infect Dis. 2017 Feb;55:102-108
pubmed: 28104505
Eur J Intern Med. 2017 May;40:64-71
pubmed: 27979670
Lancet. 2013 Apr 20;381(9875):1380-1390
pubmed: 23369797
J Microbiol Immunol Infect. 2012 Dec;45(6):453-8
pubmed: 22823943
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
PLoS One. 2009 Nov 11;4(11):e7776
pubmed: 19936224
Expert Rev Vaccines. 2017 Nov;16(11):1095-1105
pubmed: 28971707
BMC Public Health. 2016 Dec 7;16(1):1233
pubmed: 27927201
Tunis Med. 2011 Dec;89(12):905-9
pubmed: 22198891
Nihon Rinsho. 2016 May;74(5):839-42
pubmed: 27254956
BMC Infect Dis. 2016 Aug 09;16:390
pubmed: 27506837
J Epidemiol Glob Health. 2017 Jun;7(2):123-130
pubmed: 28188119